 Shares of Sarepta Therapeutics Inc. SRPT, -0.15 were up 4.6 in premarket trading on Monday after the company said U.S. regulators accepted its application for accelerated approval of SRP-9001, its experimental treatment for Duchenne muscular dystrophy. The Food and Drug Administration is expected to make a decision whether to approve SRP-9001 by May 29. 